At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 249 enrolled
Drug / intervention
Tislelizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
In Brief
A Phase 2 clinical trial evaluating Tislelizumab for Hepatocellular Carcinoma (HCC). Completed, enrolled 249 participants across 54 sites in 8 countries.
Detailed Summary
This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma (HCC)
CountriesChina, France, Germany, Italy, Poland, Spain, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartApr 2018
Primary CompletionJun 2021
Study CompletionJul 2022
TodayJul 2026
First PostedFeb 5, 2018
Enrollment StartApr 9, 2018
Primary CompletionJun 30, 2021
Study CompletionJul 6, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.4 years ago
Interventions
Tislelizumabdrug
Administered intravenously